NDAORALTABLETPriority Review
Approved
Jul 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
EFFIENT (prasugrel hydrochloride) by Molecular Devices is p2y 12 class of adp receptors on platelets. First approved in 2009.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EFFIENT (prasugrel hydrochloride) is an oral P2Y12 adenosine diphosphate receptor antagonist approved in 2009 for acute coronary syndrome. It works by inhibiting platelet aggregation to reduce thrombotic cardiovascular events. This antiplatelet agent is administered as an oral tablet and represents a key therapeutic option in cardiology.
$0.039BPart D
LOE ApproachingDeclining
With LOE approaching and low current spending ($39K in Part D claims), brand teams face contraction; roles are shifting toward generic transition support or deprioritization.
Mechanism of Action
P2Y 12 class of ADP receptors on platelets.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on EFFIENT offers limited career growth due to its LOE-approaching lifecycle stage and minimal job openings (0 linked positions). Professionals on this team face contraction risk as the brand transitions toward generic competition and deprioritization.
Brand ManagerCommercial Manager
Worked on EFFIENT at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.